New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
The participation in scientific congresses is firmly established in the event agenda of any pharmaceutical company. But what is happening behind the doors of congress centers? How do patients benefit from the participation of pharmaceutical represent
Our colleague Trent on how his purpose transformed his life
Trent, a Professional Services Veterinarian, found his purpose in creating an environment that fosters mental and physical wellbeing for others and himself